Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Celerion Appoints Executive Director, Applied Translational Medicine

Published: Tuesday, June 04, 2013
Last Updated: Monday, June 17, 2013
Bookmark and Share
Dr. Bruce Morimoto will have responsibility for developing and implementing strategies for patient populations in early clinical research and clinical pharmacology studies.

Celerion  announces the appointment of Dr. Bruce Morimoto as Executive Director of Applied Translational Medicine. Dr. Morimoto will also assume leadership for the External Studies Management and Clinical Monitoring Services teams.

The appointment of Dr. Morimoto reinforces Celerion’s focus on delivering Applied Translational Medicine. Celerion is focused on applying our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines.

Dr. Morimoto comes to Celerion with over 20 years of experience in the pharmaceutical and biotechnology industries as well as in contract research organizations (CRO). Prior to joining Celerion, he was Vice President of Drug Development at Allon Therapeutics, where his focus was to manage their neurodegeneration and dementia therapeutic programs including preclinical, manufacturing and clinical development. Dr. Morimoto also held positions at MDS Pharma Services, a full service CRO; Neuromed Technologies, a biotech company developing novel pain therapeutics; Phoenix International Life Sciences, a global CRO; and Amur Pharmaceuticals, a biopharmaceutical company focused on diabetes and drug delivery research.

Dr. Morimoto’s hands-on drug development experience that includes program, project and portfolio management, combined with an understanding of the CRO industry, provides him with invaluable insight into how best to tackle the inclusion of patients in both clinical pharmacology as well as Phase IIa Proof-of-Concept studies.

“We are very pleased to have Bruce join the Drug Development Services team at Celerion,” said Susan Thornton Ph.D, President and CEO of Celerion. “His in-depth knowledge of drug development as well as focus on Applied Translational Medicine from both the client and CRO perspective will be a great asset to our organization.”

Dr. Morimoto earned his doctorate in biochemistry from the University of California, Los Angeles (UCLA), completed post doctorate research at University of California, Berkeley, and was also on the faculty in the Chemistry department at Purdue University.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Celerion Opens Operations in South Korea at SNUH Clinical Trial Center
Partnership with Seoul University Hospital provides access to 80-bed clinical research unit.
Friday, March 07, 2014
Celerion Opens Operations in South Korea

Friday, March 07, 2014
Celerion Appoints New Executive Director
Celerion announced the appointment of Dr. Bruce Morimoto as Executive Director of Applied Translational Medicine.
Wednesday, May 22, 2013
Celerion Announces Expanded State-of-the-Art ADME Suite
The state-of-the-art ADME Suite benefits from on-site bioanalytical services and Phase I clinical facilities to offer clients a one stop solution.
Friday, May 18, 2012
Celerion and Ricerca Biosciences Announce Formation of “The Biosimilars Alliance”
Offers clients a more effective development path for biosimilars.
Friday, March 02, 2012
Celerion Appoints Dr Raymond Farmen as Vice President of Global Bioanalytical Services
Dr Farmen will have responsibility for the company’s bioanalytical operations in Zurich, Switzerland and Lincoln, Nebraska USA.
Friday, July 08, 2011
Celerion Receives ANVISA Certification
Brazilian Regulatory Agency approves Celerion facilities in both North America and Europe to conduct clinical research and bioanalytical services.
Friday, June 24, 2011
Celerion Recognized as Member of the UK Respiratory Therapeutic Capability Cluster
Celerion will work with key decision makers and thought leaders in the UK to develop and execute Phase I and IIa studies with targeted patient populations.
Friday, April 08, 2011
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
New Mechanism of Plant RNA Degradation Identified
Researchers have identified a novel mechanism by which RNA is degraded.
Achieving “Green” Desalination
Workshop explores ways to reduce or eliminate the carbon footprint of seawater desalination plants.
NIH Contributes to Global Effort to Prevent and Manage Lung Diseases
The large scale trial will measure health benefits of clean cookstoves.
Study Finds Key Regulator in Pulmonary Fibrosis
Researchers identify an enzyme that could open the way to therpies for chronic fatal lung disease.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos